Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.35 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19104774 | 0.73 | RAB9A (0.51) | SMN1; SMN2CYP1A2CYP3A4GAACYP2D6 | |
| SCHEMBL5353045 | 0.70 | GSK3B (0.56) | CYP1A2CYP3A4GAANAPRTCYP2D6 | |
| SCHEMBL7428115 | 0.68 | NAPRT (0.45) | CYP1A2CYP3A4GAANAPRTCYP2D6 | |
| SCHEMBL7933884 | 0.67 | NAPRT (0.48) | CYP1A2CYP3A4GAANAPRTCYP2D6 | |
| SCHEMBL1887807 | 0.67 | CYP1A2 (0.51) | CYP1A2CYP3A4GAANAPRTCYP2D6 | |
| SCHEMBL31484455 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2CYP1A2CYP3A4CYP2C19KDM4E | |
| SCHEMBL476302 | 0.67 | — | — | |
| Bromide SCHEMBL4188500 | 0.66 | CYP1A2 (0.50) | CYP1A2CYP3A4GAANAPRTCYP2D6 | |
| SCHEMBL4962554 | 0.66 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP3A4CA1GAA | |
| SCHEMBL18949188 | 0.66 | LMNA (0.55) | CYP1A2CYP3A4NAPRTCYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2019-09-10 | — | — | US | disclosed |
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | OHIO UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | OHIO UNIVERSITY (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | OHIO UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | OHIO UNIVERSITY (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392381-B2 | Prevention and treatment of non-alcoholic fatty liver disease | FABP1, LIPC, SLC10A1 | SMN1; SMN2 3263/4885CYP1A2 185/4885CYP3A4 516/4885 |
| US-10407420-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | SMN1; SMN2 4867/4885CYP1A2 322/4885CYP3A4 289/4885 |
| US-20170196845-A1 | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, LIPC, SLC10A1 | SMN1; SMN2 3263/4885CYP1A2 185/4885CYP3A4 516/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | SMN1; SMN2 4866/4885CYP1A2 314/4885CYP3A4 282/4885 |
| US-20170210737-A1 | IMIDAZOLE AND THIAZOLE COMPOSITIONS FOR MODIFYING BIOLOGICAL SIGNALING | FGFR1, TYRO3, STAT6 | SMN1; SMN2 4873/4885CYP1A2 416/4885CYP3A4 375/4885 |
| US-10023567-B2 | Imidazole and thiazole compositions for modifying biological signaling | FGFR1, TYRO3, STAT6 | SMN1; SMN2 4873/4885CYP1A2 416/4885CYP3A4 375/4885 |
| US-20170202818-A1 | METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY | GSK3B, GSK3A, GSKIP | SMN1; SMN2 398/4885CYP1A2 3932/4885CYP3A4 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.